We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App

New Blood Testing Method Detects Potent Opioids in Under Three Minutes

By LabMedica International staff writers
Posted on 26 Feb 2024
Print article
Image: The microfluidic open interface system (Photo courtesy of University of Waterloo)
Image: The microfluidic open interface system (Photo courtesy of University of Waterloo)

Fentanyl, an opioid 50 times more potent than heroin, presents a major risk to public health. In recent years, there's been a growing concern over the rise in fentanyl use among drug users. Annually, this potent drug is responsible for thousands of overdose deaths globally. In response to this crisis, a breakthrough in drug testing has been achieved. Now, researchers have developed a new blood testing method capable of detecting powerful opioids, including fentanyl, more rapidly than traditional methods, thereby offering a potential lifeline in overdose situations.

This innovative method developed by a team at the University of Waterloo (Ontario, Canada) can simultaneously analyze up to 96 blood samples for the presence of opioids like fentanyl in less than three minutes, a rate that's double the speed of existing methods. To conduct the test, a small volume of blood is placed into each well of a 96-well plate, which also contains a phosphate buffer. This plate is then inserted into a device that shakes the samples. Next, a solid phase microextraction (SPME) probe is used to target and extract the drugs of interest. The final step involves analyzing the sample with a mass spectrometer connected to a microfluidic open interface. Impressively, this process yields results in approximately 90 seconds.

"The difference between our blood testing method and traditional methods used in laboratories and hospitals is that we can do it faster and reach the same conclusion," said Emir Nazdrajić, a postdoctoral fellow in Waterloo's Department of Chemistry. "Let's say someone who has overdosed is in the emergency room, and doctors need to quickly determine what they've taken to treat them effectively. The speed of our method can be lifesaving."

"There is a high demand for rapid screening methods using mass spectrometry (MS) that can decrease the turnaround time, cost, and limits of quantitation of existing methodologies," added Dr. Janusz Pawliszyn, a professor in Waterloo's Department of Chemistry. "Our method targets not only fentanyl but other drugs and certain types of diseases."

Related Links:
University of Waterloo

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
All-in-one Molecular Diagnosis System
Panall 8000

Print article


Molecular Diagnostics

view channel
Image: Protein ‘signatures’ obtained via a blood sample can be used to predict the onset of 67 diseases (Photo courtesy of Queen Mary University of London)

Protein Signatures in Blood Can Predict Risk of Developing More Than 60 Diseases

Measuring specific proteins to diagnose conditions like heart attacks, where troponin is tested, is a well-established clinical practice. Now, new research highlights the broader potential of protein measurements... Read more


view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more


view channel
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically... Read more


view channel
Image: The tool can improve precision oncology by accurately predicting molecular subtypes and therapy responses (Photo courtesy of Shutterstock)

Computational Tool Integrates Transcriptomic Data for Improved Breast Cancer Diagnosis and Treatment

Breast cancer is the most commonly diagnosed cancer globally, presenting in various subtypes that require precise identification for effective, personalized treatment. Traditionally, cancer subtyping has... Read more


view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.